Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
09 déc. 2024 16h01 HE
|
Chimerix, Inc.
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 déc. 2024 16h01 HE
|
Chimerix, Inc.
DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement...
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
11 nov. 2024 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
07 nov. 2024 07h00 HE
|
Chimerix, Inc.
– Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review...
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
01 nov. 2024 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 oct. 2024 16h31 HE
|
Chimerix, Inc.
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
03 sept. 2024 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
30 août 2024 16h05 HE
|
Chimerix, Inc.
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
13 août 2024 07h00 HE
|
Chimerix, Inc.
– Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose...
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
06 août 2024 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...